NCT03379259 2024-10-26
Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors
BeiGene
Phase 1/2 Terminated
BeiGene
Shanghai Jun Pai Ying Shi Therapeutics Co., Ltd.
T-knife GmbH
Antengene Corporation
Eisai Inc.
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
Bristol-Myers Squibb